openPR Logo
Press release

Junior Research Prize 2009 for Neuromuscular Diseases is awarded by Temmler Pharma

04-20-2009 07:31 PM CET | Health & Medicine

Press release from: Temmler Group

Dr. Bernhard Neundörfer, Dr. Gabriela-Elena Oprea, Prize Winner, Melanie Kornder, Product Manager Temmler Pharma, Dr. Reinhard Dengler, Hanover.

Dr. Bernhard Neundörfer, Dr. Gabriela-Elena Oprea, Prize Winner, Melanie Kornder, Product Manager Temmler Pharma, Dr. Reinhard Dengler, Hanover.

Temmler Pharma GmbH & Co. KG founds the Junior Research Prize of the German Society for Muscular Diseases e.V. (DGM)

The Junior Research Prize has been awarded to Gabriela-Elena Oprea from the Institute for Human Genetics in Cologne, in line with the 19th Congress of the Scientific Advisory Council of the German Society for Muscular Diseases. Dr. Oprea received this award for her innovative discovery of a protective gene in spinal muscular atrophy (SMA). The €2,500 prize, which has already been awarded for six years, is funded by Temmler Pharma for the research of rare neuromuscular diseases.

Spinal muscular atrophy (SMA) is one of the most frequently occurring recessive, genetic diseases in human beings; characterized by the degeneration of the motor neurons in the spinal cord. This causes a symmetrical weakening of the muscles and atrophy of the leg, arm and eventually the entire torso musculature. This genetic disease has lead to early childhood death in many cases. Dr. Oprea’s extraordinary research has made it possible to identify a fully protective modified gene for an inherited disease for the first time. In addition, a significant contribution has been made to better understanding spinal muscular atrophy (SMA).

The discovery of a protective gene gives scientists and patients across the world hope that therapeutic treatments for this often deadly disease will soon be discovered.

In the central nervous system sector, supplements for rare neurological diseases, such as Huntington’s disease and Myasthenia gravis, are sold alongside generics. By awarding the Junior Research Prize, Temmler Pharma is making a significant contribution to researching these and other diseases, which are often neglected due to the small number of patients affected by them.

By successfully combining innovative technology and comprehensive services, Temmler would like to open up new market potential for our customers in the health care sector, thereby providing them with notable competitive advantages.

Temmler offers services across the entire contract manufacturing process, and thereby ensures a seamless transition between the individual stages of value-adding. From development to production to worldwide distribution, comprehensive services have been developed which cover virtually all requirements in the pharmaceutical contract manufacturing market.

Temmler Pharma GmbH & Co. KG
Temmlerstr. 2
D-35039 Marburg
GERMANY
E-Mail: info@temmler.eu
Web: http://www.temmler.eu

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Junior Research Prize 2009 for Neuromuscular Diseases is awarded by Temmler Pharma here

News-ID: 76197 • Views:

More Releases from Temmler Group

Customers’ demands are being met even faster - Flexible, quick, efficient and affordable packaging with Temmler Pharma in Marburg
Customers’ demands are being met even faster - Flexible, quick, efficient and …
In order to continue to meet Temmlers customers’ demands in a more efficient, more flexible and more affordable manner in the long term, a second, identically constructed thermoform machine (CP200) with cartoner P1600 was put into operation at the headquarters in Marburg. With the new packaging line 1, up to overall 80 million blisters a year can now be manufactured in a three shift system. Part of the CP200 concept

More Releases for Pharma

Miglitol Market Size, Share and Forecast By Key Players-Weiao Pharma, Zhejiang M …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Miglitol market is anticipated to grow at a compound annual growth rate (CAGR) of 11.49% between 2024 and 2031. The market is expected to grow to USD 22.32 Billion by 2024. The valuation is expected to reach USD 47.79 Billion by 2031. The Miglitol market is experiencing significant growth due to the rising prevalence of diabetes and the increasing awareness of the
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031. The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasing
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031. The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. As
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis. Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382 The Indomethacin Global Market Research Report provides close monitoring
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 …
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024. Global Roxatidine Market overview: Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the